Safety and Efficacy of Ranibizumab for Diabetic Macular Edema

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The primary objective of the study is to assess the ocular and systemic adverse events of ranibizumab (Lucentis)for DME (diabetic macular edema) following previous treatment with intravitreal bevacizumab (Avastin).
Epistemonikos ID: 580219cb5487a285735ce52d99e2dd4ebac86ea3
First added on: May 11, 2024